

Listing of Claims:

Claim 1 (previously cancelled)

Claim 2 (previously cancelled)

Claim 3 (previously cancelled)

Claim 4 (previously cancelled)

Claim 5 (previously cancelled)

Claim 6 (previously cancelled)

Claim 7 (previously cancelled)

Claim 8 (previously amended): A modified recombinant allergen wherein at least one of the T-cell reactive regions 16-42, 135-149 and 180-206 of the Ph1 p 5b polypeptide of SEQ ID NO: 87, consisting of a total of 265 amino acids, is not altered.

Claim 9 (previously amended): A modified recombinant allergen according to claim 8, selected from the group consisting of:

| | | |
|-----|---|---------------------|
| PM1 | (N ³² → D, D ⁴⁹ → L, K ⁵⁰ → A) | (SEQ ID NO. 88) |
| PM2 | (D ⁴⁹ → L, K ⁵⁰ → A) | (SEQ ID NO. 89) |
| PM3 | (A ¹³ → C) | (SEQ ID NO. 90) |
| DM1 | (Δ K ⁵⁰ → P ^{Δ132} , D ⁴⁹ → L) | (SEQ ID NO. 91) |
| DM2 | (Δ F ⁵¹ - G ¹⁷⁸ , D ⁴⁹ - L, K ⁵⁰ - A) | (SEQ ID NO. 92) and |
| DM3 | (Δ A ¹⁵⁴ - T ¹⁷⁷ , A ²²⁰ → T) | (SEQ ID NO. 93). |

§Appl. No. 09/381,903
Amdt. dated August 29, 2003
Reply to Office Action of July 1, 2003

Claim 10 (withdrawn).

Claim 11 (previously amended): A pharmaceutical preparation for treating an IgE-mediated allergy comprising at least one modified recombinant allergen according to claim 8 and a pharmaceutically acceptable carrier.

Claim 12 (withdrawn).

Claim 13 (currently amended) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a pharmaceutical composition comprising a modified recombinant allergen according to claim + 8 and a pharmaceutically acceptable carrier.

Claim 14 (currently amended) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim + 8.

Claim 15 (previously added): The pharmaceutical preparation according to claim 11 comprising a physiologically compatible salt or solvate of said recombinant modified allergen.

Claim 16 (previously added): The pharmaceutical preparation according to claim 11 comprising an additional active compound.

Claim 17 (previously amended): A modified recombinant allergen having a region which corresponds to at least one of the T-cell reactive regions 16-42, 135-149, and 180-206 of the Ph1 p 5b polypeptide of SEQ ID NO: 87, consisting of a total of 265 amino acids, wherein at least one of said regions is not altered.

Claim 18 (previously added): A modified recombinant allergen of claim 17, wherein a combination of said regions is present and is not altered.

Claim 19 (previously amended): A modified recombinant allergen according to claim 17, selected from the group consisting of:

| | | |
|-----|---|--|
| PM1 | (N ³² → D, D ⁴⁹ → L, K ⁵⁰ → A) | (SEQ ID NO. 88) |
| PM2 | (D ⁴⁹ → L, K ⁵⁰ → A) | (SEQ ID NO. 89) |
| DM1 | (Δ K ⁵⁰ → P ^{Δ132} , D ⁴⁹ → L) | (SEQ ID NO. 91) or <u>and</u> |
| DM3 | (Δ A ¹⁵⁴ - T ¹⁷⁷ , A ²²⁰ → T) | (SEQ ID NO. 93). |

Claim 20 (previously amended): The modified recombinant allergen according to claim 8, wherein said modification refers to a wild type polypeptide that is altered by a substitution.

§Appl. No. 09/381,903
Amdt. dated August 29, 2003
Reply to Office Action of July 1, 2003

Claim 21 (previously amended): The modified recombinant allergen according to claim 17, wherein said modification refers to a wild type polypeptide that is altered by a deletion.

Claim 22 (previously added): An allergen of claim 8, wherein a combination of said regions is present and is not altered.

Claim 23 (withdrawn):

Claim 24 (newly added) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 9 which is DM1 or DM3.

Claim 25 (newly added) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 17.

Claim 26 (newly added) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 19 which is PM1 or PM3.

§Appl. No. 09/381,903
Amdt. dated August 29, 2003
Reply to Office Action of July 1, 2003

Claim 27 (newly added) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 20.

Claim 28 (newly added) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 21.

Claim 29 (newly added) A method of immunospecific therapy (hyposensitization) of allergies, comprising administering to a patient in need thereof a modified recombinant allergen according to claim 22.